CareDx (CDNA)
(Delayed Data from NSDQ)
$8.95 USD
+0.12 (1.36%)
Updated Mar 24, 2023 04:00 PM ET
After-Market: $8.96 +0.01 (0.11%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth A Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating indiv idual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$8.95 USD
+0.12 (1.36%)
Updated Mar 24, 2023 04:00 PM ET
After-Market: $8.96 +0.01 (0.11%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth A Momentum B VGM
Zacks News
CareDx (CDNA) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
CareDx (CDNA) delivered earnings and revenue surprises of -16.67% and 0.38%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Viatris (VTRS) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Viatris (VTRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: CareDx (CDNA) Q4 Earnings Expected to Decline
by Zacks Equity Research
CareDx (CDNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
UnitedHealth's (UNH) Optum to Boost Northern Light's Efficiency
by Zacks Equity Research
Per the deal, around 1,400 employees of Northern Light are likely to shift to UnitedHealth's (UNH) Optum this March.
HCA Healthcare (HCA) Unit in Talks to Buy Wise Health System
by Zacks Equity Research
HCA Healthcare's (HCA) deal with Wise Health System is expected to boost its footprint and market share in Texas.
Molina's (MOH) California Medicaid Revenues to Double in 2024
by Zacks Equity Research
Molina Healthcare (MOH) expects combined revenues from California, Nebraska, and Iowa in 2024 to reach $4.2 billion.
Why Hold Strategy is Apt for Centene (CNC) Stock Right Now
by Zacks Equity Research
Centene's (CNC) health benefits ratio is expected to improve in the coming days, signaling better operating efficiency.
Molina Healthcare (MOH) to Incur $200M Impairment Charge in Q4
by Zacks Equity Research
The reduction of Molina Healthcare's (MOH) real estate footprint is expected to result in a sizeable decline in leased real estate expense.
Here's Why CareDx (CDNA) Could be Great Choice for a Bottom Fisher
by Zacks Equity Research
CareDx (CDNA) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
CareDx (CDNA) Loses 22.5% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
by Zacks Equity Research
CareDx (CDNA) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
CareDx (CDNA) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
CareDx (CDNA) delivered earnings and revenue surprises of 57.14% and 2.82%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Avantor, Inc. (AVTR) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
Avantor, Inc. (AVTR) delivered earnings and revenue surprises of 3.03% and 0.68%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Icon PLC (ICLR) Surges 3%: Is This an Indication of Further Gains?
by Zacks Equity Research
Icon PLC (ICLR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
CareDx (CDNA) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
CareDx (CDNA) delivered earnings and revenue surprises of -62.50% and 3.05%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
CareDx (CDNA) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
CareDx (CDNA) delivered earnings and revenue surprises of -225% and 1%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
CareDx (CDNA) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
CareDx (CDNA) delivered earnings and revenue surprises of -250% and 0.66%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Acushnet Holdings, CareDx, Lululemon and Chewy highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Acushnet Holdings, CareDx, Lululemon and Chewy highlighted as Zacks Bull and Bear of the Day
Bear Of The Day:CareDX
by Brian Bolan
This stock has beaten the Zacks Consensus Estimate in each of the last four quarters but it has fallen to the lowest Zacks Rank.
CareDx (CDNA) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
CareDx (CDNA) delivered earnings and revenue surprises of 133.33% and 1.82%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: CareDx (CDNA) Q3 Earnings Expected to Decline
by Zacks Equity Research
CareDx (CDNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CareDx (CDNA) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
CareDx (CDNA) delivered earnings and revenue surprises of 120.00% and 9.07%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
CareDx (CDNA) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
CareDx (CDNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CareDx (CDNA) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
CareDx (CDNA) delivered earnings and revenue surprises of 1500.00% and 10.91%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
CareDx (CDNA) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
by Zacks Equity Research
CareDx (CDNA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The Zacks Analyst Blog Highlights: MACOM Tech, CrowdStrike, Zscaler, CareDx and Medifast
by Zacks Equity Research
The Zacks Analyst Blog Highlights: MACOM Tech, CrowdStrike, Zscaler, CareDx and Medifast